



Press Release

2 December 2009

The SOHO Group invests seed funding in Gamma Vaccines

The SOHO Group, Indonesia's fastest growing manufacturer of pharmaceutical products and herbal medicines has made a seed investment of A\$600,000 in Gamma Vaccines Pty Ltd.

The SOHO Group became a strategic investor in Gamma Vaccines in December 2009. The SOHO Group has established a close working partnership with Gamma Vaccines and is proactively assisting the company in its engagement with other partners in Indonesia.

Professor Tim Hirst, Executive Chairman of Gamma Vaccines commented "We are very pleased to have secured an investment from such a large and well-respected Indonesian company. Indonesia is a large and important market for new medical treatments and we are hopeful of furthering our relationships there so we can progress to clinical trials of our novel "universal flu vaccine"

About Gamma Vaccines

Gamma Vaccines Pty Ltd is a new company that is developing a novel vaccine approach to preventing influenza infections. The company's proprietary product is a vaccine that offers broad protective immunity against a wide diversity of influenza virus A strains. The company has received grant assistance from the Commercialising Emerging Technologies (COMET) program of the Australian Federal Government and from the ACT Government's Innovation Connect (ICoN) scheme.

About The SOHO Group

The SOHO Group is the oldest and third largest pharmaceutical company in Indonesia. Over the past five years it has also been Indonesia's fastest growing pharma company, employing over 4,500 people with revenue growth of over 25% p.a.

The SOHO Group manufactures and distributes medicines from global pharmaceutical companies as well as its own proprietary products.

Contacts

For further information about Gamma Vaccines, please contact:

Professor Tim Hirst
Executive Chairman
Gamma Vaccines Pty Ltd
Tel: +61 (0) 420 942 824
e-mail: tim@gammavaccines.com